Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38482   clinical trials with a EudraCT protocol, of which   6323   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-005508-33
    Sponsor's Protocol Code Number:MC-FludT.16/NM
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-08-08
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2013-005508-33
    A.3Full title of the trial
    Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseases
    A.3.2Name or abbreviated title of the trial where available
    Treosulfan-based versus Busulfan-based conditioning in paediatric patients with non-malignant diseas
    A.4.1Sponsor's protocol code numberMC-FludT.16/NM
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/033/2014
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of Sponsormedac GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportmedac GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationINC Research UK Limited
    B.5.2Functional name of contact pointGhalia Hachem
    B.5.3 Address:
    B.5.3.1Street Address1 Pinehurst Road,
    B.5.3.2Town/ cityFarnborough, Hants,
    B.5.3.3Post codeGU14 7BF
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number0031 1207528717
    B.5.6E-mailGhalia.Hachem@Syneoshealth.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ovastat 1000 (Treosulfan injection)
    D.2.1.1.2Name of the Marketing Authorisation holdermedac GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/04/186
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTREOSULFAN
    D.3.9.1CAS number 299-75-2
    D.3.9.4EV Substance CodeSUB11235MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ovastat 5000 (Treosulfan injection)
    D.2.1.1.2Name of the Marketing Authorisation holdermedac GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/04/186
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTREOSULFAN
    D.3.9.1CAS number 299-75-2
    D.3.9.4EV Substance CodeSUB11235MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Busilvex
    D.2.1.1.2Name of the Marketing Authorisation holderPierre Fabre Medicament
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/00/011
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBUSULFAN
    D.3.9.1CAS number 55-98-1
    D.3.9.4EV Substance CodeSUB05993MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Male and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.
    E.1.1.1Medical condition in easily understood language
    Children with non-malignant diseases requiring conditioning treatment prior to stem cell transplantation
    E.1.1.2Therapeutic area Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10021606
    E.1.2Term Inborn errors of metabolism NEC
    E.1.2System Organ Class 100000004850
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10036700
    E.1.2Term Primary immunodeficiency syndromes
    E.1.2System Organ Class 100000004870
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10018903
    E.1.2Term Haemoglobinopathies congenital
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Comparative evaluation of freedom from transplant (treatment)-related
    mortality (TRM), defined as death from any transplant-related cause
    from start of conditioning treatment (day -7) until day +100 after HSCT.
    E.2.2Secondary objectives of the trial
    Comparative evaluation of:
    1. Neutropihil and platelet engraftment after HSCT.
    2. Safety including early toxicity (defined as toxicities occurring until day
    +28), until day +100 after HSCT, SARs until the end of longer-term
    follow-up phase.
    3. HSOS, lung toxicity, hepatic toxicity and infections of any CTCAE grade
    until day +100.
    4. Chimerism on day +28, day +100 and 12 months after HSCT.
    5. OS until 12 months after HSCT.
    6. Graft failure until 12 months after HSCT.
    7. Acute (until day +100) and chronic (until 12 months after HSCT)
    GvHD.
    8. Use of rescue therapies including DLIs, stem cell infusions with or
    without further conditioning regimens, re-occurrence of transfusion
    dependence (i.e. necessity of regular transfusions of red blood cells or
    platelets.
    9. PK parameters of Treosulfan and its epoxides and to develop a PK
    model for assessing relevant covariates.
    10. Graft failure, cGvHD, donor-type chimerism, OS and TRM during the
    longer-term follow-up phase.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Non-malignant disease indicated for first myeloablative allogeneic
    HSCT, including inborn errors of metabolism, primary
    immunodeficiencies, haemoglobinopathies and bone marrow failure
    syndromes.
    2. First allogeneic HSCT.
    3. Available matched sibling donor (MSD), matched family donor (MFD)
    or matched unrelated donor (MUD). For bone marrow (BM) and
    peripheral blood (PB) match is defined as at least 9/10 allele matches
    after four digit typing in human leucocyte antigen (HLA)-A, -B, -C, –
    DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is
    defined as at least 5/6 matches after two digit typing in HLA-A and -B
    and four digit typing in DRB1 antigens.
    4. Age at time of registration from 28 days to less than 18 years of age.
    5. Lansky (patients <16 years of age) or Karnofsky (patients ≥ 16 years
    of age) performance score of at least 70%.
    6. Written informed consent of the parents/legal guardians and patient's
    assent/consent according to national regulations.
    7. Female patients of child-bearing potential or partner of male patients
    with child-bearing potential must use a highly effective method of
    contraception (pearl index < 1%) such as complete sexual abstinence,
    combined oral contraceptive, hormone intrauterine contraceptive device
    (IUCD), vaginal hormone ring, transdermal contraceptive patch,
    contraceptive implant or depot contraceptive injection in combination
    with a second method of contraception like a condom or a cervical cap /
    diaphragm with spermicide or surgical sterilisation (vasectomy) in male
    patients or male partners during the study and at least six months
    thereafter. For female patients on the study, the vasectomized male partner should be the sole partner for this patient.
    8. Negative pregnancy test for females of child-bearing potential.
    E.4Principal exclusion criteria
    1. Second or later HSCT.
    2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood
    stem cells (PBSC) or less than 5/6 matched cord donor).
    3. Preterm newborn infants (<37 weeks gestational age) and term
    newborn infants aged 0 – 27 days at time of registration.
    4. Obese paediatric patients with body mass index weight (kg)/[height
    (m)]² > 30 kg/m².
    5. Diagnosis of Fanconi anaemia and other chromosomal breakage
    disorders, radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase
    4, Cernunnos- X-ray repair cross-complementing protein 4 (XRCC4) like
    factor (XLF), Nijmegen Breakage Syndrome (NBS)) and Dyskeratosis
    Congenita.
    6. Treatment with cytotoxic drugs within 10 days prior to day 7.
    7. Impaired liver function indicated by Bilirubin > three times the upper
    limit of normal (ULN) or aspartate aminotransferase/alanine
    aminotransferase (AST/GOT, ALT/GPT) > ten times ULN or clinically significant coagulopathy, or active
    infectious hepatitis with clinical evidence.
    8. Impaired renal function indicated by estimated glomerular filtration
    rate ([GFR], according to the Schwartz formula) < 60 mL/min/1.73m2.
    9. Impaired cardiac function: severe cardiac insufficiency indicated by
    left ventricular ejection fraction (LVEF)  35%.
    10. Requirement for supplementary continuous oxygen.
    11. Severe active infection requiring deferral of conditioning.
    12. Human immunodeficiency virus (HIV) positivity.
    13. Severe concomitant illness, comorbidity or condition that would
    severely limit life expectancy.
    14. Known pregnancy, breast feeding.
    15. Known hypersensitivity to Treosulfan, Busulfan, Fludarabine and/or
    Thiotepa.
    16. Participation in another interventional clinical study with an
    experimental drug, within four weeks prior to patient inclusion.
    E.5 End points
    E.5.1Primary end point(s)
    Comparative evaluation of freedom from transplant (treatment)-related
    mortality (TRM), defined as death from any transplant-related cause
    from start of conditioning treatment (day -7) until day +100 after HSCT.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day +100 after HSCT
    E.5.2Secondary end point(s)
    1. Comparative evaluation of engraftment after HSCT, defined as the first
    of three consecutive days for each of the following four criteria:
    - a leukocyte count of more than 1 x 109/L
    - an absolute neutrophil count (ANC) of more than
    0.5 x109/L
    - a platelet count of at least 20 x109/L
    - a platelet count of at least 50 x109/L.
    2. Comparative evaluation of safety including early toxicity (defined as
    toxicities occurring until day +28), based on Common Terminology
    Criteria for Adverse Events (CTCAE) version 4.03 until day +100 after
    HSCT, serious adverse reactions (SARs) until the end of longer-term
    follow-up phase (three years after HSCT of last patient).
    3. Comparative evaluation of hepatic sinusoidal obstruction syndrome
    (HSOS), lung toxicity (CTCAE term pulmonary fibrosis), hepatic toxicity
    (according Bearman's criteria) and infections of any CTCAE grade (nonserious
    and serious) until day +100.
    4. Comparative evaluation of donor-type chimerism on day +28, day
    +100 and 12 months after HSCT.
    5. Comparative evaluation of overall survival (OS) until 12 months after
    HSCT.
    6. Comparative evaluation of primary and secondary graft failure until 12
    months after HSCT.
    7. Comparative evaluation of incidence and severity of acute (until day
    +100) and chronic (until 12 months after HSCT) graft versus host
    disease (aGvHD/cGvHD).
    8. Comparative evaluation of use of rescue therapies including donorlymphocyte
    infusions (DLIs), stem cell infusions with or without further
    conditioning regimens, re-occurrence of transfusion dependence (i.e.
    necessity of regular transfusions of red blood cells or platelets.
    9. Evaluation of PK parameters of Treosulfan and its epoxides and to
    develop a PK model for assessing relevant covariates.
    10. Comparative evaluation of secondary graft failure, cGvHD, donortype
    chimerism, OS and TRM during the longer-term follow-up phase.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Day +28, day +100 and 12 months after HSCT and/or until the end of the longer-term follow-ip phase.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA17
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Subsequent to the 12-months follow-up, all patients will be followed on a yearly basis for a minimum of two additional years. This longer-term follow-up phase is scheduled until three years after HSCT of the last
    patient enrolled into the study. The end of the trial is defined as last follow-up visit of last subject.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 100
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) Yes
    F.1.1.4.1Number of subjects for this age range: 40
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 40
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 20
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Children below 18 years of age
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After study participation, patients will receive treatment/medical care as routinely used in medical conditions after conditioning treatment and subsequent allogeneic stem cell transplantation.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-11-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-09-18
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA